No Detail Found!

Comparison of Metformin and Pioglitazone in Achieving Sustained Virological Response in Chronic Hepatitis C Patients with Insulin Resistance: a Quasi-experimental Study.

Author(s)
Imran Mahfooz Khan Department of Medicine, King Edward Medical University, Lahore, Pakistan
Bilal Rafique Malik East Medical Ward, Mayo Hospital, Laho
Fawad Ahmad Randhawa Department of Medicine/Endocrinology, King Edward Medical University, Lahore,
Nasir Farooq Butt Department of Medicine, King Edward Medical University, Lahore, Pakistan
Uzma Malik Department of Medicine, King Edward Medical University, Lahore, Pakistan
Shahid Hamid Department of Medicine, King Edward Medical University, Lahore, Pakistan
Abstract
Objective: To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients. Methods: This quasi-experimental, comparative, interventional study was conducted at Mayo Hospital, Lahore, Pakistan, from January 2015 to March 2016, and comprised chronic hepatitis C patients who had insulin resistance. The patients were divided evenly in three groups. Group A had patients treated with interferon 3 million units, three times in a week and ribavirin 400mg three times in a day. In addition to interferon and ribavirin, group B was treated with metformin, and group C received pioglitazone. Polymerase chain reaction was done at the completion of 24 and 48 weeks to assess the end treatment and sustained virological response, respectively. SPSS 20 was used for data analysis. Results: Of the 138 patients, there were 46(33.3%) in each group. The mean age of the patients in group A was 36.83±9.65 years, in group B was 37.72±10.00 years and in group C it was 38.07±8.85 years. Overall, there were 70(50.72%) males and 68(49.28%) females. At the end of 24 weeks, polymerase chain reaction exhibited that in group A, the score was 100 in 18(39.1%) patients. In group-B, it was 100 in 7(15.2%) patients. In group-C, it was 100 in 15(32.6%) patients. The sustained virological response was considerably higher in group B (p=0.003) Conclusion: Sustained virological response with standard therapy with metformin gave high-end response as compared to other groups.
Publication Details
Page(s) 1848-1852
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 67, Issue: 12, Year: 2017

Request the full text from PASTIC

Keywords
NULLL
References
AyeleA,Gebre-SelassieS.,Hepatitis C Virus,,2013,Infections among Patients with Chronic Liver Diseases in Public Hospitals in Addis Ababa, Ethiopia,ISRN Tropical Med,,1,7
SchaeferM,CapuronL,FriebeA,Diez-QuevedoC,RobaeysG,NeriS,,2012,Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement,J Hepatol,57,1379,90
QureshiH,BileK,JoomaR,AlamS,AfridiH,,2010,Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures,Eastern Med Health J,16,S15,
FarooqiJI,FarooqiRJ,,2008,Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3,J Coll Physicians Surg Pak,18,620,4
RehanHS,ManakS,YadavM.,,2014,Supervised conventional interferon ?2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C,Ind J Pharmacol,46,490,2
EslamM,KhattabM,Harrison S,,2011,Peroxisome proliferator-activated receptors and hepatitis C virus,Therapeut Adv Gastroenterol,4,419,31
Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a metaanalysis. J Hepatol 2011; 55: 1187-94.
YuJW,SunLJ,ZhaoYH,KangP,YanBZ,,2012,The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance,Int J Infect Dis,16,e436,e41
ChojkierM,ElkhayatH,SabryD,DonohueM,BuckM.,,2012,Pioglitazone decreases hepatitis C viral load in overweight, treatment naive, genotype 4 infected-patients: a pilot study,PloS one,7,e31516,
HarrisonSA,HamzehFM,HanJ,PandyaPK,SheikhMY,VierlingJM,,2012,Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin,Hepatology,56,464,73
AlbertiA,VarioA,FerrariA,PistisR,,2005,Review article: chronic hepatitis C-natural history and cofactors,Alimentary Pharmacol Therapeut,22,74,8
Romero-GómezM,Del Mar ViloriaM,AndradeRJ,SalmerónJ,DiagoM,Fernández-RodríguezCM,,2005,Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients,Gastroenterology,128,636,41
AsselahT,Rubbia-BrandtL,MarcellinP,NegroF.,,2006,Steatosis in chronic hepatitis C: why does it really matter,Gut,55,123,30
Negro F.,,2006,Insulin resistance and HCV: will new knowledge modify clinical management,J Hepatol,45,514,9
GinesP,AngeliP,LenzK,MollerS,MooreK,Moreu R. European,DeltenreP,LouvetA,LemoineM,MouradA,FartouxL,MorenoC,,2011,Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a metaanalysis,J Hepatol,55,1187,94
Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a metaanalysis. J Hepatol 2011; 55: 1187-94.
Overbeck K, Genné D, Golay A, Negro F, Liver SAftSot. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-? and ribavirin. J Hepatol 2008; 49: 295-8.
Romero Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández Rodríguez CM, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa 2a plus ribavirin. Hepatology 2009; 50:1702-8.
Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, et al. Pioglitazone improves virological response to peginterferon ??2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-54
0

Citations

0

Downloads

73

Views